Furthermore, the Inhibition of IL-17 with drugs, including brodalumab, ixekizumab (IXE), and secukinumab (SEC), has been shown to provide a robust clinical response and a significant improvement in psoriasis patients’ quality of life (25). The gene discussed is IL17A; the disease is psoriasis.